Is RNAZ or RPRX more undervalued in 2026?

CirclFi compares TransCode Therapeutics, Inc. (RNAZ) and Royalty Pharma plc (RPRX) using 13 institutional-grade valuation models. RNAZ has a Quality of Company score of 3.9/10 while RPRX scores 8.4/10.

Which is a better buy — RNAZ or RPRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RNAZ and RPRX valuations compare?

RNAZ at $5.29 and RPRX at $54.48 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RNAZ vs RPRX Valuation Comparison 2026 — Intrinsic Value Analysis

RNAZ

Biotechnology

TransCode Therapeutics, Inc.

Quality

3.9

out of 10

Value Trap

LOW

Price

$5.29

Last close

Models

6/13

Active

RPRX

Biotechnology

Royalty Pharma plc

Quality

8.4

out of 10

Value Trap

SAFE

Price

$54.48

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	RNAZ Fair Value	RNAZ Upside	RPRX Fair Value	RPRX Upside
Bayesian DCF	Intrinsic	$8.80	+66.4%	$57.58	+5.7%
Earnings Power Value	Intrinsic	—	—	$1.77	-96.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$17.68	+234.2%	$49.54	-9.1%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RNAZ vs RPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RNAZ vs RPRX — Which Stock Is More Undervalued?

RPRX scores higher with a 8.4/10 quality rating vs RNAZ's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing TransCode Therapeutics, Inc. (RNAZ) and Royalty Pharma plc (RPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RNAZ currently trades at $5.29 with a QOC of 3.9/10, while RPRX trades at $54.48 with a QOC of 8.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).